INTRODUCTION

Top Abstract Introduction Materials and Methods Results Discussion References

One of the earliest consequences of lymphocyte antigen receptor triggering is the activation of phosphoinositide-specific phospholipase C- (PLC) (67). PLC hydrolyzes phosphatidylinositol (4,5)-bisphosphate (PtdInsP₂) to inositol (1,4,5)-trisphosphate and diacylglycerol, metabolites which control calcium mobilization and protein kinase C activation, respectively (3, 40, 41). Together these second messengers coordinate the activation of downstream signaling pathways that ultimately control the metabolic and biological response of the cell.

PLC is a cytoplasmic enzyme that, in order to hydrolyze PtdInsP₂, needs to both translocate to the membrane where its substrate resides and undergo an increase in its intrinsic catalytic potential (2, 57). Tyrosine phosphorylation of PLC is an obligatory step that augments its catalytic activity (2, 21, 30) and allows PLC to overcome the substrate sequestration and inhibitory effect of the actin- and phosphoinositide-binding protein, profilin (11).

Two structurally related PLC isozymes, PLC1 and PLC2, have been identified (3, 40). Receptor tyrosine kinases, like the epidermal growth factor (EGF) receptor or the platelet-derived growth factor (PDGF) receptor, recruit PLC1 to their intracellular autophosphorylated tails and phosphorylate PLC1 by way of their intrinsic tyrosine kinase activity (31, 62, 63). The antigen receptors of T and B lymphocytes, however, have no intrinsic kinase activity. These receptors recruit protein tyrosine kinases via their immunoreceptor tyrosine-based activation motifs, leading to the activation of several signaling cascades, including the PLC-regulated Ca²⁺ pathway (68). In both T and B lymphocytes, PLC1 and/or PLC2 are tyrosine phosphorylated (4, 14, 32, 43, 67) and have been found in association with several signaling molecules, including the CD3 chains of the T-cell receptor (TCR) (6), kinases of the Src and Syk families (24, 36, 37, 49, 65), and adapter molecules such as Grb2 (48), Slp76 (19), BLNK/Slp65 (9, 10, 70), or pp36-38/LAT (48, 66, 73).

Studies using cells with altered signaling molecules have demonstrated that Lck (53), Zap70 (71), Itk (25), and the adapter, Slp76 (72), play a role in TCR-induced PLC1 tyrosine phosphorylation and/or activation in T lymphocytes. In B lymphocytes, both PLC isoforms are activated in response to B-cell receptor (BCR) engagement (4, 14, 43). Expression of Syk is necessary for PLC phosphorylation and activation in B lymphocytes (56). Furthermore, Syk can phosphorylate PLC in vitro (24). However, coexpression of a functional BCR together with Fyn and Syk in nonlymphoid cells does not induce PLC phosphorylation or Ca²⁺ mobilization (42), suggesting that additional molecules may be involved in coupling PLC to Syk. The recently identified adapter, BLNK/Slp65 (9, 10, 18, 70), may serve such a coupling function. An additional tyrosine kinase involved in PLC phosphorylation in B lymphocytes is the Tec family kinase, Btk, as shown by the defective tyrosine phosphorylation of PLC2 in Btk-deficient cells (55). Btk and its T-lymphocyte counterpart, Itk, may play a role in controlling the antigen receptor-induced PLC activation that lead to a sustained Ca²⁺ influx (8, 25, 55).

Despite the large number of molecules shown to interact with PLC isozymes, the mechanism of PLC activation by the lymphocyte antigen receptors remains largely undefined. The involvement of multiple molecules in PLC activation suggests the presence of a complex molecular network regulating PLC translocation, phosphorylation, and catalytic activity. These activation events, while highly interrelated, are likely to be regulated in a manner independent of one another. To gain further insights into the mechanism of PLC activation, we sought to explore the relationship between certain PLC structural features and the sequence of activation events induced by BCR engagement.

Both PLC1 and PLC2 have two Src homology 2 (SH2) domains and a single SH3 domain. SH2 domains bind tyrosine-phosphorylated proteins and may interact with certain phospholipids (34, 38). SH2 domains are highly conserved modular regions of ~100 residues containing an Arg residue at the structurally conserved position B5, which coordinates the interaction with the phosphorylated tyrosine (33, 64). The selectivity of binding by SH2 domains is primarily conferred by the amino acid in position D5 (Cys in either SH2 domain of PLC1 or PLC2), which makes contact with residues at the +1 and +3 positions immediately carboxy terminal to the phosphotyrosine of the bound peptide (50). Both SH2 domains of PLC belong to a group that recognizes target sequences with the motif pY-hydrophobic-X-hydrophobic, although amino acid differences within this consensus may further select between the SH2 N-terminal [SH2(N)] and SH2 C-terminal [SH2(C)] domains (50).

SH3 domains bind proteins that contain proline-rich regions (34). The PLC1 SH3 domain has an apparent binding preference for proteins containing a PPVP motif (47, 51), with sequences surrounding the SH3 domain contributing to the stabilization of the core interaction (12). The specific function of this domain in PLC activation, however, remains uncertain. Because a fusion protein encompassing the SH3 domain of PLC1 codistributed with cytoskeletal structures (1), it has been proposed that this domain may function in targeting PLC1 to the cell cytoskeleton and possibly contribute to bringing the active enzyme in proximity of its substrate.

To further explore the role of PLC1 SH domains in activation, we have expressed wild-type PLC1 and PLC1 variants bearing functional mutations of the SH2 domains or the SH3 domain in the PLC-deficient B-cell line, P10-14 (54). These cells do not express PLC1, and PLC2 expression has been disrupted by gene targeting. The effect of these mutations on BCR-induced PLC1 translocation, phosphorylation, and activity has revealed a critical role for each domain at various points in the activation sequence.

	MATERIALS AND METHODS

Top Abstract Introduction Materials and Methods Results Discussion References

Cells and reagents. The parental chicken B-cell line, DT-40, the PLC-deficient derivative, P10-14 (54), and stable PLC1 P10-14 transfectants were all maintained in RPMI 1640 containing 7.5% fetal bovine serum and 1% chicken serum. The anti-influenza virus hemagglutinin (HA) antibody, 12CA5, was a gift from Allan Weissman (National Cancer Institute, National Institutes of Health, Bethesda, Md.). The antiphosphotyrosine antibody (Ab), 4G10, was from Upstate Biotechnology (Lake Placid, N.Y.). The PLC1 glutathione S-transferase (GST)-SH2(N) domain and GST-SH2(C) domain fusion proteins were from Santa Cruz Biotechnology. The GST-Grb2 fusion protein construct (46) was a gift from Pier Giuseppe Pelicci (European Oncology Institute, Milan, Italy). The rabbit anti-chicken BLNK serum (amino acids 79 to 201) has been previously described (18). The NF-AT luciferase reporter gene construct was a gift from Gerald Crabtree (Stanford University, Stanford, Calif.).

DNA plasmids, transfections, and generation of stable transfectants. The construction of the HA-tagged bovine PLC1 (PLC1-HA) in the expression vector, pCIneo (Promega, Madison, Wis.), and the site-directed mutagenesis of the SH2(N) domain (Arg to Lys at position 586) and the SH2(C) domain (Arg to Lys at positions 694 or 694 and 696) have been described previously (52). A mutation of Pro to Leu at position 842 within the SH3 domain was introduced by PCR using appropriate oligonucleotides. The amplified fragment was shuttled via BSSHII and StuI sites into a pBluescript SK vector (Stratagene, La Jolla, Calif.) which encoded bovine PLC1. A fragment encompassing the SH3 domain-coding region was excised with EcoRV and SacII and ligated in the identical position of PLC1-HA in the pCIneo expression vector. The loss of binding by the SH2 domain mutants was validated by encoding the same mutations as GST fusion proteins (52). Loss of function of the SH3 domain mutant was demonstrated by the failure of a GST fusion protein encoding the proline-rich region of c-Cbl to precipitate PLC1-HA SH3^P842L compared to the wild-type (WT) protein (data not shown). The amino-terminal myristoylation (myr) signal sequence, (M)GSSKKSKPKD, and the control sequence, (M)ASSKKSKPKD, were introduced by PCR using appropriate oligonucleotides and ligated directly into PLC1-HA in pCIneo via XbaI and Eco72I sites. All transfections were performed by electroporation as previously described (52). For the preparation of stable transfectants, P10-14 cells were electroporated with 20 µg of the indicated PLC1-HA construct and 2 µg of pBABEpuro (29) and selected with puromycin (Sigma, St. Louis, Mo.). Different sets of clones stably expressing closely matched levels of WT and SH domain mutants of PLC1 were screened by anti-HA immunoblotting and selected for further analysis.

Cell activation. BCR stimulation was routinely accomplished by treating cells with a polyclonal goat anti-chicken immunoglobulin M (IgM) purified antiserum (Bethel Laboratories, Montgomery, Tex.) for 1 min at 37°C. In some experiments, cells were coated on ice with the goat anti-chicken IgM Ab, washed, and stimulated for 1 min at 37°C with a rabbit anti-goat IgG purified antiserum (Jackson Immunoresearch, West Grove, Pa.). For induction of phosphoinositide hydrolysis, the anti-chicken IgM was immobilized onto 3 µM polystyrene latex beads (Polysciences, Warrington, Pa.) at 100 µg/10⁹ beads.

Immunofluorescence. Stable PLC1-HA transfectants were activated, fixed with 3.7% formaldehyde, and permeabilized by immersion in methanol 70%. Slides were incubated with the anti-HA monoclonal Ab (diluted 1:10,000 in phosphate-buffered saline containing human immunoglobulins [4 mg/ml] and goat immunoglobulins [4 mg/ml]) and then reacted with a fluorescein isothiocyanate (FITC)-conjugated goat anti-mouse Ab (DAKO Sp.A., Milan, Italy) diluted 1:30. Analysis was carried out with a TCS 4D (Leica) mounted on a Leitz DMRB microscope equipped with a 100×/1.3 NA oil immersion objective. High-resolution fluorescence images were obtained by exciting fluorescein at 488 nm. Serial optical sections, acquired with an averaging function line by line, top down, with a scanning mode format of 512 by 512 pixels, were elaborated by a three-dimensional image processing system providing an extended focus image.

Cell fractionation. Cells (30 × 10⁶ cells) were resuspended in hypotonic buffer (10 mM Tris-HCl [pH 7.5] containing 0.5 mM MgCl₂ plus protease and phosphatase inhibitors). After 10 min on ice, cells were subjected to Dounce homogenization, NaCl was added to restore tonicity along with EDTA, and samples were centrifuged (550 × g, 5 min) to remove nuclei and unbroken cells. The particulate (membrane) fraction was separated from the cytosol by ultracentrifugation at 100,000 × g for 60 min. Membrane-containing pellets were washed extensively and resuspended in lysis buffer (50 mM Tris-HCl [pH 7.5], 300 mM NaCl, 0.5% Triton X-100, protease and phosphatase inhibitors), and the solubilized material was recovered by centrifugation (10,000 × g for 15 min). After determination of the protein concentration in the cytosol and solubilized particulate fractions, identical amounts of proteins were resolved by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and immunoblotted as described below.

Precipitation and Western blot analysis. Cells were lysed in a buffer comprised of 60 mM Tris-HCl (pH 7.8) containing 150 mM NaCl, 5 mM EDTA, 10% glycerol, 1% Triton X-100, and phosphatase and protease inhibitors as previously described (52). Postnuclear fractions were precipitated with GST fusion proteins bound to glutathione-Sepharose beads (Pharmacia, Piscataway, N.J.) or specific Ab prebound to protein A-Trisacryl beads (Pierce, Rockford, Ill.). Proteins were eluted with sample buffer, resolved by SDS-PAGE under reducing conditions, and transferred to nitrocellulose membranes (Hybond-C Super; Amersham, Arlington Heights, Ill.). Protein detection was via primary Ab with or without second Ab (rabbit anti-mouse IgG; Cappel, Aurora, Ohio) followed by [¹²⁵I]protein A (ICN, Costa Mesa, Calif.). For certain experiments, immunoblots were stripped according to the membrane manufacturer's instructions and reprobed with other Abs followed by detection with [¹²⁵I]protein A or the Amersham ECL system. Radioimmunoblots were scanned on a PhosphorImager (Molecular Dynamics, Sunnyvale, Calif.) to produce the images shown (ImageQuant software; Molecular Dynamics) with no manipulation, except for the adjustment of the exposure range. All experiments shown were repeated at least three times.

Phosphoinositide hydrolysis. Cells were labeled with [myo-³H]inositol (7.5 µCi/0.5 × 10⁷ cells/ml; Amersham) for 4 h at 37°C. Activation was accomplished by mixing cells with anti-chicken IgM-coated polystyrene beads and incubating in the presence of 10 mM LiCl at 37°C for 45 min. Reactions were terminated by the addition of trichloroacetic acid. The soluble material was applied to an AG1-X8 column, and total inositol phosphates were eluted with 1 M ammonium formate containing 0.1 M formic acid. Precipitable material was dissolved in 10% Triton X-100 and used to determine the amount of [³H]inositol incorporated into the phospholipid pool. Data were normalized as the percentage of the total cellular radioactivity.

Measurement of NF-AT transcriptional activity. Cells were transfected with 10 µg of a plasmid containing a luciferase reporter under the control of the interleukin 2 minimal promoter and three optimized NF-AT enhancer elements (pNF-AT-luc) together with 10 µg of pAD (Clontech, Palo Alto, Calif.), a control vector for transfection efficiency in which the expression of -galactosidase is regulated by the adenovirus major late promoter. After 24 h, 2 × 10⁵ cells were incubated for additional 6 h in 100 µl of medium containing 10 µg of anti-chicken IgM. Cells were washed twice, disrupted in lysis buffer (Promega), and assayed using luciferin (Promega). Data were normalized by assaying for -galactosidase activity using Galacton Plus and Emerald Enhance (Tropix, Bedford, Mass.).

PLC assay. Cells (2.5 × 10⁷ cells/sample) stably expressing the various PLC1-HA constructs were treated with medium alone or activated with anti-chicken IgM antiserum. Lysates were clarified by centrifugation, and postnuclear fractions were subjected to immunoprecipitation with an anti-HA Ab as described above. Samples from untransfected P10-14 cells were always included as negative controls. The immunoprecipitates were washed extensively and assayed for PLC activity by using a modification of the method described by Wahl et al. (60). For this assay, 1 mg of PtdInsP₂ (Roche Diagnostic) and 2 µCi of [³H]PtdInsP₂ (New England Nuclear) were combined, dried, resuspended in 180 µl of 50 mM NaH₂PO₄ (pH 6.8), and 100 mM KCl, and sonicated. -Octylglucoside was then added to a final concentration of 50 mM in a total volume of 360 µl. The assay mix (50 µl) included 100 mM NaH₂PO₄ (pH 6.8), 175 mM KCl, 2 mM EGTA, 2 mM CaCl₂, 0.07% Triton X-100 (final concentration, 1.2 mM), and 5 µl of the micellar suspension of PtdInsP₂ (final concentration, ~250 µM). The assay was conducted at 35°C and started by the addition of the substrate. The assay was terminated at the indicated times with the addition of 10% ice-cold trichloroacetic acid and serum albumin as a carrier. Samples were centrifuged, and the acid-soluble radioactivity was determined by -scintillation counting.

	RESULTS

Top Abstract Introduction Materials and Methods Results Discussion References

The SH2(N) and SH3 domains of PLC1 are involved in BCR-induced membrane translocation of PLC1. The P10-14 cell line was derived from the chicken B-cell line, DT40, and expresses no detectable PLC isozymes (54). P10-14 cells were transfected with expression vectors encoding a HA-tagged PLC1 WT protein or PLC1 proteins bearing mutations of the SH domains. Stable cell lines with similar levels of PLC1-HA expression (data not shown) were established. The role of PLC1 SH domains in BCR-induced membrane translocation was explored first by immunofluorescence studies of stable PLC1-HA transfectants activated via Ab-mediated BCR aggregation and probed with an anti-HA-FITC. In unstimulated B cells, WT PLC1-HA was present as a diffuse cytoplasmic fluorescence (Fig. 1A). Within 1 min of treatment with anti-BCR stimulation, a portion of WT PLC1 localized to the cell membrane and the juxtamembrane areas, as indicated by a strong reinforcement of the fluorescence signal at and immediately below the cell rim. No membrane redistribution was observed in cells expressing the SH2(N) domain PLC1-HA mutant (Fig. 1B). Mutation of PLC1 SH2(C) domain (double mutation of Arg at positions 694 and 696 to Lys) had no effect on BCR-induced PLC1 membrane association (Fig. 1C). A reduction in the stimulated redistribution of the SH3 domain mutant PLC1-HA was also observed (Fig. 1E), with the edge of the cells expressing the SH3 domain mutant showing a distinct fluorescent granularity rather than a continuous pattern of reinforcement in response to BCR stimulation. A PLC1 construct bearing a double mutation of both the SH2(N) and SH2(C) domains failed to translocate to the membrane and was indistinguishable from the single PLC1 SH2(N) domain mutant (Fig. 1D). Results obtained by fluorescence microscopy were confirmed by cell fractionation experiments. Western blots of membranes from stable transfectants expressing WT PLC1 and the SH2(C) domain mutant showed an increase in PLC1-HA compared to unactivated control cells (Fig. 2). No stimulated increase was observed in the membrane preparation from the PLC1 SH2(N) domain mutant, while only a partial increase was detected in that of the PLC1 SH3 domain mutant. These data suggest that an intact SH2(N) domain is absolutely required for BCR-induced PLC1 membrane translocation, whereas the SH3 domain contributes some additional redistribution function. The SH2(C) domain plays no apparent role in receptor-induced translocation of PLC1.

View larger version (43K): [in this window] [in a new window]   FIG. 1.   BCR-induced translocation of PLC1 to the cell membrane is affected by mutation of the SH2(N) domain or SH3 domain. Stable transfectants, expressing similar levels of PLC1-HA by Western blot analysis, were treated with medium (left panels, Cont) or anti-chicken IgM (right panels, Stim) for 1 min, fixed with formaldehyde, permeabilized, reacted with anti-HA Ab, and stained with a secondary FITC-conjugated antiserum as described in Materials and Methods. (A) PLC1-HA WT; (B) PLC1-HA SH2(N)R586K; (C) PLC1-HA SH2(C)R694/6K; (D) PLC1-HA SH2(N/C)R586/694/6K; (E) PLC1-HA SH3P842L.

View larger version (44K): [in this window] [in a new window]   FIG. 2.   BCR-induced translocation of PLC1 to the membrane fraction is affected by mutation of the SH2(N) domain and SH3 domain. (A) Stable transfectants expressing WT PLC1-HA were precoated with a murine anti-chicken IgM monoclonal Ab and stimulated for 1 min at 37°C with a rabbit anti-mouse IgG Ab. Medium-treated (uncoated) cells or cells treated only with the rabbit anti-murine IgG serum (Sec Ab) were included as controls. Cytosol and particulate (membrane) fractions were resolved by SDS-PAGE and immunoblotted with anti-HA. (B) Resolubilized membrane fractions from control- or BCR-activated (1 min at 37°C) stable transfectants expressing identical levels of the indicated PLC1-HA WT and mutant proteins were resolved by SDS-PAGE and immunoblotted with anti-HA.

BCR-induced tyrosine phosphorylation of PLC1 requires a functionally intact SH2(N) domain capable of interacting with the adapter molecule, BLNK. BCR aggregation induces rapid tyrosine phosphorylation of PLC1 and PLC2 in B cells (4, 14, 43), an event which is required for PLC activation. We therefore performed anti-HA immunoprecipitation experiments from resting and activated P10-14 cells expressing PLC1-HA proteins followed by antiphosphotyrosine immunoblotting. WT PLC1-HA was tyrosine phosphorylated in P10-14 cells following BCR engagement (Fig. 3). The level of tyrosine phosphorylation of the SH2(N) domain mutant, however, was significantly less than that of the WT protein. Mutation of a single or both critical Arg residues to Lys in the SH2(C) domain had no discernible effect on BCR-induced tyrosine phosphorylation of PLC1-HA. Similarly, mutation of the SH3 domain did not decrease the stimulated level of tyrosine phosphorylation of PLC1. Identical results were obtained in several stable transfectants as well as in transient transfection experiments (data not shown), suggesting that the differences observed cannot be attributed to clonal variations. Therefore, BCR-induced PLC1 tyrosine phosphorylation was exclusively dependent on the function of the SH2(N) domain.

View larger version (64K): [in this window] [in a new window]   FIG. 3.   BCR-induced tyrosine phosphorylation of PLC1 requires an intact SH2(N) domain. Stable WT or SH mutant PLC1-HA transfectants were stimulated with anti-chicken IgM for 1 min at 37°C. Anti-HA immunoprecipitates were resolved by SDS-PAGE and immunoblotted with antiphosphotyrosine (upper panels). The same blots were stripped and reprobed with anti-HA (lower panels) for comparison of the relative amounts of PLC1-HA expressed. HC, heavy chain; LC, light chain.

View larger version (40K): [in this window] [in a new window]   FIG. 4.   pp80 binds the SH2 domains of PLC1 or Grb2. (A) Untransfected P10-14 cells were treated with medium or anti-chicken IgM for 1 min. Lysates were precipitated with GST alone or with the GST-SH2(N) or GST-SH2(C) domain fusion protein of PLC1 or a GST-Grb2 fusion protein immobilized onto glutathione-Sepharose beads. Lysates from stable P10-14 transfectants expressing WT PLC1-HA were subjected to immunoprecipitation (IP) with anti-HA. Proteins were resolved by SDS-PAGE and immunoblotted with antiphosphotyrosine. (B) Lysates from stable P10-14 transfectants expressing WT PLC1-HA were immunoprecipitated with anti-HA or were sequentially precipitated with three rounds of GST-Grb2 fusion protein followed by anti-HA immunoprecipitation. Proteins were resolved by SDS-PAGE and immunoblotted with antiphosphotyrosine. HC, heavy chain; LC, light chain.

View larger version (37K): [in this window] [in a new window]   FIG. 5.   The PLC1 SH2(N) domain-bound pp80 is BLNK. (A) Stable P10-14 transfectants expressing WT PLC1-HA or PLC1-HA SH2(N)R586K domain mutant were treated for 1 min at 37°C with medium alone or anti-chicken IgM. Lysates were immunoprecipitated with anti-HA and proteins resolved by SDS-PAGE. Blots were probed with antiphosphotyrosine (upper panels) and stripped and reprobed with anti-chicken BLNK (lower panels). (B) Lysates from activated WT PLC1-HA transfectants were immunoprecipitated (IP) with anti-HA or were sequentially immunoprecipitated with anti-chicken BLNK followed by anti-HA immunoprecipitation. Samples were resolved by SDS-PAGE and immunoblotted with antiphosphotyrosine. HC, heavy chain.

Forced membrane localization of PLC1 does not overcome the SH2(N) requirement for tyrosine phosphorylation. The SH2(N) domain is involved in both BCR-induced membrane translocation and tyrosine phosphorylation of PLC1. To determine if the inability of the SH2(N) domain mutant of PLC1 to be phosphorylated could be primarily attributed to its defect in membrane translocation, PLC1-HA was forced to the membrane by the addition of a myr sequence (39). Cell fractionation experiments confirmed that a greater percentage of the myr-PLC1-HA constructs repartitioned to the membrane fraction compared to control constructs in which the amino-terminal myristoyl acceptor Gly was mutated to Ala (GA) (Fig. 6A and B) or with the unmodified WT protein (data not shown). The amount of transiently expressed myr-PLC1-HA constitutively associated to the membrane fraction (~25%) exceeded the amount of stably expressed WT PLC1-HA repartitioned to this fraction upon BCR engagement (~10% [data not shown]). The presence of cytosolic myr-PLC1-HA was likely due to the limited ability of transiently transfected cells to modify the overexpressed protein. The resting level of phosphorylation of myr-PLC1-HA constructs transiently expressed in P10-14 cells was comparable to that of the GA controls (Fig. 6C). BCR-stimulated tyrosine phosphorylation of myr-PLC1-HA WT was also similar to that of the GA PLC1-HA WT control. BCR-induced tyrosine phosphorylation, however, was abrogated by mutation of the SH2(N) domain regardless of its myristoylation (Fig. 6C). Addition of a myr signal to the SH2(C) or SH3 domain mutants did not affect the resting or stimulated phosphorylation status of these proteins (data not shown). These data indicate that targeting PLC1 to the membrane via a myr signal sequence does not bypass the need for the SH2(N) domain to interact with a protein that promotes PLC1 tyrosine phosphorylation. They further suggest that PLC1 tyrosine phosphorylation is not controlled by simple membrane/cytosol compartmentalization.

View larger version (52K): [in this window] [in a new window]   FIG. 6.   Membrane targeting of PLC1 via myristoylation does not bypass the SH2(N) domain requirement for BCR-induced tyrosine phosphorylation. (A) P10-14 cells were transiently transfected with 20 µg of pCIneo PLC1-HA WT or pCIneo PLC1-HA SH2(N)R586K containing an amino-terminal Src myr myr sequence or a control sequence (cont). After 24 h, cells were lysed by Dounce homogenization and fractionated into cytosol (Cyto) and membrane (Membr) components. Twenty-five micrograms of protein was resolved by SDS-PAGE and immunoblotted with anti-HA. (B) Densitometric analysis of the blot shown in panel A. (C) Transiently transfected P10-14 cells were treated for 1 min with medium or anti-chicken IgM. Lysates were immunoprecipitated with anti-HA, resolved by SDS-PAGE, and probed with antiphosphotyrosine (upper panel). The same blot was stripped and reprobed with anti-HA (lower panel) for comparison of the relative amounts of PLC1-HA expressed. HC, heavy chain; LC, light chain.

Both PLC1 SH2(N) and SH2(C) domains are required for BCR-induced phosphoinositide hydrolysis and NF-AT signaling. PLC1 catalyzes the hydrolysis of inositol phospholipids resulting in the generation of diacylglycerol, which activates protein kinase C and several inositol phosphates, including inositol (1,4,5)-trisphosphate (40). To establish the role of PLC1 SH domains in BCR-induced enzyme activation, P10-14 transfectants expressing PLC1-HA WT or mutant constructs were labeled with [myo-³H]inositol and stimulated via BCR ligation in the presence of lithium chloride to block inositol phosphate phosphatases. The accumulated inositol phosphates were separated from free inositol by ion-exchange chromatography. Whereas untransfected P10-14 cells showed no stimulated generation of inositol phosphates, activity was restored by expressing the PLC1-HA WT (Fig. 7A), with inositol phosphate accumulation levels similar to that of the parental DT-40 cells (data not shown). BCR engagement, however, did not stimulate inositol phosphate production in cells expressing the SH2(N) mutant PLC1-HA, consistent with its lack of membrane translocation and phosphorylation. Furthermore, inositol phospholipid hydrolysis was also abrogated in cells expressing PLC1-HA bearing mutations of the SH2(C) domain and partially reduced in cells expressing a PLC1-HA with a mutated SH3 domain. These results indicate that all SH domains must be functional for full PLC1 enzymatic activity in response to BCR ligation and that steps in addition to tyrosine phosphorylation and membrane translocation control PLC1 activation.

View larger version (43K): [in this window] [in a new window]   FIG. 7.   PLC1 SH domains are required for BCR-induced phosphoinositide hydrolysis and NF-AT induction. (A) Cells (2 × 106) expressing PLC1-HA WT and mutant constructs were labeled with [3H]inositol, washed, and incubated with 5 × 107 3-µm-diameter polystyrene beads precoated with bovine albumin or anti-chicken IgM. Inositol phosphates were allowed to accumulated for 45 min at 37°C in the presence of 5 mM LiCl and separated from free inositol by ion-exchange chromatography. Data are expressed as the percentage of total cell-associated radioactivity (mean ± standard deviation of three separate experiments). The inset represents the data normalized per the resting, unstimulated levels of inositol phosphates (stimulation index). (B) Stable PLC1-HA transfectants were transiently transfected with pNF-AT-Luc and pAD for 24 h. Cells were stimulated for 6 h with plate-immobilized anti-chicken IgM, harvested, lysed, and assayed for luciferase and -galactosidase activities. Specific NF-AT activity is expressed as the luciferase/-galactosidase (b-gal) ratio (mean ± standard deviation of three separate experiments). The inset represents the data normalized per the resting, unstimulated NF-AT activity (stimulation index).

The SH2(N) and SH2(C) domains affect the in vitro enzymatic activity of PLC1. To further investigate the function of the SH2 domains, the enzymatic activity of PLC1 was tested in anti-HA immunoprecipitates from resting and activated P10-14 cells expressing WT PLC1 or the SH2 domain mutants. The in vitro assay was performed at pH 6.8 and used a suspension of the substrate, PtdInsP₂, with Triton X-100 to yield a PtdInsP₂/Triton X-100 micellar molar ratio of 1:3.8 (assuming a nominal critical micellar concentration for Triton X-100 of 0.24 mM). These conditions were experimentally determined to give an optimal differential between nonactivated and BCR-stimulated PLC activity (data not shown). Under these experimental conditions, WT PLC1-HA from medium-treated cells demonstrated PtdInsP₂ hydrolytic activity that was linear for up to 6 min upon addition of the substrate (Fig. 8). Such activity was kinetically increased in PLC1 recovered from BCR-activated cells, consistent with the BCR induction of PLC1 phosphorylation and phosphoinositide hydrolysis observed in intact cells. The SH2(N) domain mutant of PLC1 demonstrated only basal levels of in vitro activity, irrespective of BCR aggregation. These levels were identical to those observed with the WT protein from unstimulated cells. This finding is consistent with that lack of BCR-induced membrane translocation, tyrosine phosphorylation, and activation observed with the PLC1 SH2(N) domain mutant in vivo.

View larger version (14K): [in this window] [in a new window]   FIG. 8.   Influence of the SH2 domains on the in vitro enzymatic activity of PLC1 from resting and BCR-activated cells. Cells stably expressing PLC1-HA WT, the PLC1-HA SH2(N)R586K domain mutant, or the PLC1-HA SH2(C)R694/6K domain mutant were treated with medium alone or with anti-BCR Ab for 2 min at 37°C. Anti-HA immunoprecipitates from 2.5 × 107 cells were assayed for PLC activity by using a mixed micellar suspension of [3H]PtdInsP2 and Triton X-100 as the substrate. The activity was measured as the formation of trichloroacetic acid-soluble [3H]inositol phosphates. No acid-soluble radioactivity accumulated over time in samples precipitated from untransfected P10-14 cells (not shown), and this background radioactivity was subtracted from the experimental samples. Shown is the mean ± standard error of the mean of five separate experiments.

	DISCUSSION

Top Abstract Introduction Materials and Methods Results Discussion References

Our data indicate that the SH domains of PLC1 perform autonomous yet overlapping functions in BCR-induced activation. The SH2(N) domain is essential, having a role in membrane translocation, phosphorylation, and activation of the enzyme, while the SH2(C) domain is required for its activity but dispensable for translocation and phosphorylation. The SH3 domain contributes to BCR-induced PLC1 membrane translocation and activity but has no apparent role in phosphorylation.

Similar to its role in BCR-induced PLC1 activation, the SH2(N) domain is also essential for TCR-induced PLC1 membrane translocation (6a) and tyrosine phosphorylation (52) in Jurkat cells. The utilization of the SH2(N) domain by PLC1 for coupling to the T- or B-cell receptor contrasts with the reported preference of its SH2(C) domain for activation by the EGF or PDGF receptor (26, 44, 58, 59). This apparent preference is supported by the observation that sequences found in either the EGF or PDGF receptor (Y⁹⁹²LIP and Y¹⁰²¹IIP, respectively) match the motif selected by the isolated SH2(C) domain. The SH2(C) domain favors Pro at the +3 position, while the SH2(N) prefers Leu (50). Studies using recombinant fragments of PLC1, however, have also implicated the SH2(N) domain in binding to the intracellular tail of the phosphorylated EGF receptor (45). A sequence in the tail of the basic fibroblast growth factor (FGF) receptor (Y⁷⁶⁶LDL), on the other hand, matches the specificity of the SH2(N) domain (50), and inhibition of FGF signaling by competition with membrane-permeable tyrosine-phosphorylated peptides revealed a preference for SH2(N) domain-binding sequences (13). However, a GST fusion protein encompassing the SH2(C) domain but not the SH2(N) domain of PLC1 bound pTyr⁷⁶⁶ in a recombinant fragment of the basic FGF receptor (28). Therefore, PLC1 SH2 domains may cross-react with each other's preferred ligand. Recently, Ji and coworkers (20) have shown that the SH2(N) domain is sufficient for PLC1 to bind the phosphorylated tail of the PDGF receptor in Plc1^/ mouse embryonic fibroblasts. PDGF-induced PLC1 phosphorylation, as well as phosphoinositide hydrolysis and Ca²⁺ mobilization, however, required both SH2 domains (20). The exquisite requirement for the SH2(N) domain demonstrated by the T- or B-cell receptor not only for translocation but also for PLC1 phosphorylation suggests a coupling mechanism different from that used primarily by the PDGF or EGF receptor. This observation suggests that PLC SH2 domains may be utilized differently by different receptors.

PLC1 binds through its SH2(N) domain to the chicken homologue (18) of the recently identified adapter alternatively termed BLNK (10) or Slp65 (70). BLNK/Slp65 shares sequence homology with the T-cell-specific adapter, Slp76, a phosphoprotein required for optimal tyrosine phosphorylation and activation of PLC1 by the TCR (72). BLNK/Slp65 binds Grb2 (9, 10, 70) and can associate with either PLC1 or PLC2 in Daudi cells (10). Furthermore, coexpression of BLNK/Slp65 with PLC1 and Syk in insect cells led to increased tyrosine phosphorylation of PLC1 (10) and B cells deficient in BLNK fail to activate PLC2 (18). BLNK proteins show several conserved binding sites for PLC1 SH2 domains, albeit none displayed the motif preferred by the SH2(N) domain. The ability of both GST-SH2(N) and SH2(C) domain fusion proteins to recognize BLNK, however, suggests that PLC1 interaction with phosphorylated proteins is not exclusively regulated by the SH2 domain selectivity.

Of the SH2(N) domain-dependent functions, PLC1 membrane translocation may be the primary event which in itself could be sufficient to induce phosphorylation by promoting proximity to an active kinase. Sequestration of regulatory proteins from their targets by membrane/cytoplasmic compartmentalization is a well-known control mechanism, which includes Ras regulation by Sos (15). However, membrane targeting of PLC1-HA via an amino-terminal myr signal sequence did not result in elevated resting levels of tyrosine phosphorylation and still required a functional SH2(N) domain for BCR-stimulated PLC1 phosphorylation. These data suggest that the ability of the SH2(N) domain to mediate phosphorylation of PLC1 is not simply due to membrane translocation and that the primary function of this domain is to interact with an activation complex. Because BLNK, a cytoplasmic protein, is translocated to the cell membrane in a signal-dependent fashion (10), this molecule may nucleate an activation complex involving PLC1 and promote both its membrane translocation and phosphorylation.

The precise function of the SH2(C) domain in BCR-induced PLC1 activation remains unclear. Our data rule out a gross defect in tyrosine phosphorylation of the SH2(C) domain mutant, although a requirement for this domain in the phosphorylation of a specific tyrosine residue critical for enzyme activity cannot be completely eliminated. Three tyrosine phosphorylation sites (Tyr⁷⁷¹, Tyr⁷⁸³, and Tyr¹²⁵⁴ of the bovine PLC1 sequence) are critical for PDGF-induced enzymatic activation of PLC1 (21). A fourth additional site (Tyr⁴⁷²), whose role in PLC1 activation has not been established, is also phosphorylated in response to EGF (22, 61). While the tyrosine residues phosphorylated in response to BCR engagement are not known, a decreased overall PLC1 phosphorylation should have been observed if the SH2(C) domain mutation would have affected any of the major phosphorylation sites.

PLC assays based on substrate dispersion with surface modifiers allow discrimination of the activity from activated cells compared to that of resting cells (60). Under these assay conditions, tyrosine phosphorylation of PLC1 results in increased in vitro activity by primarily shifting the equilibrium in favor of the association of PLC1 with the micelles containing the substrate. When assayed under these conditions, PLC1 bearing a nonfunctional SH2(N) domain, which results in a protein with deficient phosphorylation in response to BCR ligation, was unable to be activated in vitro. The presence of a nonfunctional SH2(C) domain, however, resulted in a protein with constitutive in vitro activity and no longer responsive to BCR-induced activation. Several pieces of evidence indicate that the SH2-SH2-SH3 region of PLC isozymes contains regulatory elements that affect its enzymatic activity. Homma and Takenawa (16) identified an amino acid sequence immediately carboxy terminal to the SH2(C) domain that is capable of inhibiting the activity of PLC as well as that of PLC and -. Therefore, this PLC inhibitory (PCI) region may directly interact with the catalytic site, which is conserved among different phosphoinositide-specific PLC family members. While peptides limited to the PCI region display inhibitory activity with a K_i of 15 µM, the whole SH2-SH2-SH3 region shows much increased inhibitory activity (K_i = 25 nM [16]). Therefore, other elements within this region contribute to the inhibition. Furthermore, expression and assembly of the catalytic domains in the absence of the SH2-SH2-SH3 region resulted in a protein complex with increased PLC activity in vitro compared to that of the holoenzyme (7, 17). Finally, tyrosine-phosphorylated peptides capable of binding PLC1 SH2 domains can act as allosteric activators of PLC1 activity in vitro (23). Taken together with these findings, our data suggest that the SH2(C) domain of PLC1 exerts a negative control on the enzymatic activity of PLC1, possibly by an intramolecular mechanism. Consistent with this possibility, a recent study of pH dependence of PLC1 catalytic machinery presented a model whereby at neutral pH the SH2-SH2-SH3 region forms a "lid" that closes the active sites (74). Our data suggest that such a putative lid depends primarily upon an intact SH2(C) domain. It is possible that optimal positioning of the PCI peptide, which is near the SH2(C) domain, is favored by an intramolecular interaction mediated by the SH2(C) domain. Such an interaction can then be displaced in vitro either by SH2 domain ligands, whose binding is known to results in a conformational change of PLC1 (23), by decreasing the pH, resulting in protonation of residues critical for the intramolecular interaction (74), or by tyrosine phosphorylation. Therefore, the binding of SH2 domain ligands and tyrosine phosphorylation appear to be two physiologic mechanisms that can lead to a similar kinetic activation of PLC1. It remains to be determined if, under physiologic conditions, tyrosine phosphorylation occurs first and allows the SH2(C) domain to be displaced from its intramolecular interaction, whether the two events are independently regulated or are regulated with an opposite interdependency. Because tyrosine phosphorylation is necessary for enzyme activation in vivo (21), the first mechanism, which depends exclusively on the SH2(N) domain in the case of the BCR or TCR (52), appears more plausible.

In contrast with its constitutive in vitro activity, the SH2(C) domain mutant of PLC1 was unable to reconstitute the BCR-induced phosphoinositide hydrolysis in P10-14 cells. This was observed with cells stably or transiently expressing the SH2(C) domain mutant, ruling out clonal artifacts or other concerns (e.g., substrate exhaustion) due to stable expression of a potentially deregulated protein. Therefore, an interaction of the SH2(C) domain with a potential target appears necessary for BCR-induced PLC1 activation in vivo. The SH2(C) domain mutant of PLC1 did not display a pattern of coprecipitating phosphoproteins different from that of WT PLC1, although the SH2(C) domain, when expressed as a GST fusion protein, associated with several phosphoproteins (reference 52 and Fig. 4). This is consistent with structural constraints within PLC1 that prevent accessibility to the SH2(C) domain, whereas a posttranslational modification or the engagement of other domains might influence the domain's availability for interaction with other molecules. It is possible that the interaction with these molecules is weak, occurs at low stoichiometry, or is lost under our conditions of lysis, or that its phosphorylation is transient. Another possibility is that the fraction of PLC1 that is involved in SH2(C) domain-mediated interactions is relocated to a detergent-insoluble compartment (35) and selectively lost during extraction. Replacement of Triton X-100 with 60 mM -octylglucoside, a detergent capable of solubilizing membrane rafts (27), during cell solubilization failed to reveal additional coimmunoprecipitating tyrosine-phosphorylated proteins (data not shown), suggesting that within the sensitivity of our assay, the target protein is not present in this compartment. Last, the SH2(C) domain may play a role in the ability of PLC1 to bind regulatory phospholipids, such as PtdInsP₃ (38). These alternate possibilities are currently under investigation.

The SH3 domain, while dispensable for tyrosine phosphorylation, has a role in PLC1 anchoring to the membrane. Although not as critical in this function as the SH2(N) domain, it may provide a secondary level of membrane attachment. The SH3 domains of PLC1 and Src can bind cytoskeletal components (1, 69), and compartmentalization of activated PLC1 molecules to the detergent-insoluble cell cytoskeleton has been documented (35). The PLC1 SH3 domain may therefore be important for stabilizing the association of PLC1 with the membrane through the interaction with cytoskeletal elements and possibly contribute to bringing the active enzyme in proximity of its substrate.

These data are consistent with a sequential model of BCR-induced PLC1 activation whereby the different SH domains have interrelated but distinct roles. In this model, the earliest event is the engagement of the SH2(N) domain with a phosphoprotein that recruits PLC1 in an activation complex and translocates it to the membrane. PLC1 phosphorylation ensues at this stage as a consequence of the interaction of PLC1 with one or more kinases, an event mediated primarily or exclusively by the SH2(N) domain. The SH2(C) domain plays no apparent role in these events, whereas the SH3 domain contributes additional membrane anchoring, possibly by associating with cytoskeletal components. Up-regulation of PLC1 enzymatic activity depends on translocation and phosphorylation and is therefore completely abrogated by disruption of the SH2(N) domain function. The SH3 domain partially contributes to PLC1 activity, consistent with its role in membrane translocation. The SH2(C) domain, which plays a negative role in regulating the intrinsic catalytic activity of the enzyme, is absolutely required for BCR-induced PLC1 activation, possibly by binding a yet unidentified phosphoprotein or by interacting with other regulatory membrane phospholipids.